Viatris Inc. operates as a healthcare company worldwide.
$19.91+4.96%
报价 2026-11-06
市值
$22.87B
EV
$33.67B
PE (TTM)
–
预期 PE (FY2026)
7.9x
52 周区间距高点 0.0%
$10.17$19.91
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 2.56 → 2.71（1.1x） | 7.3 |
| FY+32028-12 | 1.1x | 2.56 → 2.91（1.1x） | 6.8 |
毛利率 35% · TTM 收入 $14727M · 基数 EPS 2.56（调整后）
电话会信号
辅助标签Q3 20262026-11-05
扩产需求加速上调指引供不应求
指引 上调
信心 4
分析师 4
“We expect our U.S. innovative medicines business to generate more than $1 billion in total revenue in 2027.”
原文引用（4）
- 扩产：We have actively expanded capacity through operational enhancements and expect to continue to make additional capital investments
- 需求加速：growth is accelerating as our portfolio mix shifts towards more durable, higher-margin products
- 上调指引：we are narrowing our financial guidance ranges and once again raising the midpoint for all key financial metrics
- 供不应求：We've moved from 24/5 to 24/7 utilization of that plant. We're adding a packaging line.
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| VTRSViatris Inc. | $22.87B | +5.0% | +4.6% | 38.8% | – | 12.4x | 11.2x | |
| MRNAModerna, Inc. | $101.48B | +5.3% | +9.3% | -12.6% | – | – | – | |
| ROIVRoivant Sciences Ltd. | $28.08B | +6.2% | – | 81.2% | – | – | – | |
| NBIXNeurocrine Biosciences, Inc. | $16.66B | +3.0% | +39.8% | 97.6% | 23.6x | 17.3x | 16.0x | 高增长 |
| BBIOBridgeBio Pharma, Inc. | $14.47B | +0.0% | +91.2% | 93.8% | – | – | – | |
| BAXBaxter International Inc. | $13.34B | +0.5% | +5.8% | 33.4% | – | 25.2x | 13.3x | |
| ELANElanco Animal Health Incorporated | $12.86B | +8.7% | +10.1% | 56.9% | – | 23.7x | 31.5x | GARP |
| RDYDr. Reddy's Laboratories Limited | $12.42B | +2.6% | – | 55.2% | 18.5x | 12.5x | – | |
| IONSIonis Pharmaceuticals, Inc. | $6.55B | +1.6% | -1.6% | 98.3% | – | 3.1x | – | |
| 同行中位数 | – | – | +9.7% | 69.1% | 21.1x | 17.3x | 16.0x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.76B | $3.52B | $3.7B | $3.76B | $3.58B | $3.25B | $3.53B | $3.75B |
| Gross Margin | 38.8% | 32.9% | 30.6% | 36.8% | 37.2% | 35.7% | 34.4% | 38.9% |
| Operating Margin | 0.2% | -2.3% | -7.2% | 6.7% | 6.5% | -88.6% | -5.1% | 6% |
| Net Income | $-118.8M | $176.4M | $-340.1M | $-128.2M | $-4.6M | $-3.04B | $-516.5M | $94.8M |
| Diluted EPS | -0.1 | 0.15 | -0.3 | -0.11 | -0 | -2.55 | -0.43 | 0.08 |
| Operating Cash Flow | $381.8M | $388.3M | $815.8M | $744.9M | $219.7M | $535.5M | $482.7M | $826.5M |